Developing Acute Kidney Injury CDISC Clinical Data Standards for Clinical Research and Drug Development.

制定用于临床研究和药物开发的急性肾损伤 CDISC 临床数据标准。

基本信息

  • 批准号:
    9899104
  • 负责人:
  • 金额:
    $ 9.99万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-09-01 至 2020-11-30
  • 项目状态:
    已结题

项目摘要

Project Summary/Abstract CDISC has developed foundational standards over the last twenty years and published thirty-five Therapeutic Area (TA) standards and updates for the past five years in collaboration with FDA- CDER, in addition eleven TA standards are currently in development through a community-driven, consensus-based process in collaboration with CFAST organizations and the CDISC global community of reviewers. The objectives of this project are to build on existing CDISC clinical data standards to develop vasomotor symptoms due to menopause standards that span collection (CDASH), organization (SDTM), analysis (ADaM), controlled terminology, as well as develop a number of relevant Questionnaires, Ratings or Scales (QRS), using established CDISC processes and CDISC SHARE tools. CDISC will engage CFAST stakeholders as well as the CDISC global community in the development of these new vasomotor symptoms due to menopause standards. The new vasomotor symptoms due to menopause standards will bring clarity to data and support FDA in reviewing many different studies and allowing them to ‘speak the same language’.
项目总结/摘要 CDISC在过去的二十年中开发了基础标准,并发布了35个 与FDA合作制定的治疗领域(TA)标准和过去五年的更新- CDER,此外,11个TA标准目前正在通过社区驱动的, 与CFAST组织和CDISC全球合作, 评论家社区本项目的目标是在现有CDISC临床 数据标准,以发展血管痉挛症状,由于更年期的标准, 收集(CDASH)、组织(SDTM)、分析(ADaM)、受控术语,以及 开发一些相关的量表、评级或量表(QRS),使用 建立CDISC流程和CDISC共享工具。CDISC将与CFAST 利益相关者以及CDISC全球社区参与这些新血管的开发 更年期标准的症状。更年期引起的新血管炎症状 标准将使数据更加清晰,并支持FDA审查许多不同的研究, 让他们“说同一种语言”。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sam HUME其他文献

Sam HUME的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sam HUME', 18)}}的其他基金

Leveraging CDISC innovative approaches and emerging technology to expedite development of open, end-to-end tobacco standards to facilitate regulatory submission, review and decision making.
利用 CDISC 创新方法和新兴技术加快开放、端到端烟草标准的制定,以促进监管提交、审查和决策。
  • 批准号:
    10907172
  • 财政年份:
    2021
  • 资助金额:
    $ 9.99万
  • 项目类别:
Leveraging CDISC innovative approaches and emerging technology to expedite development of open, end-to-end tobacco standards to facilitate regulatory submission, review and decision making.
利用 CDISC 创新方法和新兴技术加快开放、端到端烟草标准的制定,以促进监管提交、审查和决策。
  • 批准号:
    10413694
  • 财政年份:
    2021
  • 资助金额:
    $ 9.99万
  • 项目类别:
Leveraging CDISC innovative approaches and emerging technology to expedite development of open, end-to-end tobacco standards to facilitate regulatory submission, review and decision making.
利用 CDISC 创新方法和新兴技术加快开放、端到端烟草标准的制定,以促进监管提交、审查和决策。
  • 批准号:
    10524770
  • 财政年份:
    2021
  • 资助金额:
    $ 9.99万
  • 项目类别:
Developing Congestive Heart Failure CDISC Clinical Data Standards for Clinical Research and Drug Development.
制定用于临床研究和药物开发的充血性心力衰竭 CDISC 临床数据标准。
  • 批准号:
    9899106
  • 财政年份:
    2018
  • 资助金额:
    $ 9.99万
  • 项目类别:
Developing Psoriasis CDISC Clinical Data Standards for Clinical Research and Drug Development.
制定用于临床研究和药物开发的银屑病 CDISC 临床数据标准。
  • 批准号:
    9899108
  • 财政年份:
    2018
  • 资助金额:
    $ 9.99万
  • 项目类别:

相似海外基金

STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 9.99万
  • 项目类别:
    Standard Grant
Translocation of a gut pathobiont drives acute kidney injury
肠道病原体易位导致急性肾损伤
  • 批准号:
    23K15246
  • 财政年份:
    2023
  • 资助金额:
    $ 9.99万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Heme-mediated Mitochondrial Injury, Senescence, Acute Kidney Injury and Chronic Kidney Disease
血红素介导的线粒体损伤、衰老、急性肾损伤和慢性肾病
  • 批准号:
    10656648
  • 财政年份:
    2023
  • 资助金额:
    $ 9.99万
  • 项目类别:
Relation between acute changes in kidney function with clinical outcomes among patients with heart failure
心力衰竭患者肾功能急性变化与临床结局的关系
  • 批准号:
    10590891
  • 财政年份:
    2023
  • 资助金额:
    $ 9.99万
  • 项目类别:
Acute Kidney Injury in Children with Chronic Kidney Disease
慢性肾病儿童的急性肾损伤
  • 批准号:
    10638267
  • 财政年份:
    2023
  • 资助金额:
    $ 9.99万
  • 项目类别:
Artificial Intelligence to Predict Outcomes in Patients with Acute Kidney Injury on Continuous Renal Replacement Therapy
人工智能预测急性肾损伤患者连续肾脏替代治疗的结果
  • 批准号:
    10658576
  • 财政年份:
    2023
  • 资助金额:
    $ 9.99万
  • 项目类别:
lmmunomodulatory roles of renal lymphatic endothelial cells in Acute Kidney Injury
肾淋巴内皮细胞在急性肾损伤中的免疫调节作用
  • 批准号:
    10612171
  • 财政年份:
    2023
  • 资助金额:
    $ 9.99万
  • 项目类别:
Prevention of Nephrotoxin-induced Acute Kidney Injury with Cilastatin (PONTIAC) Trial
用西司他丁 (PONTIAC) 预防肾毒素引起的急性肾损伤试验
  • 批准号:
    485526
  • 财政年份:
    2023
  • 资助金额:
    $ 9.99万
  • 项目类别:
    Operating Grants
Regulation of Lymphatic and Vascular Remodeling in Acute Kidney Injury
急性肾损伤中淋巴和血管重塑的调节
  • 批准号:
    10750349
  • 财政年份:
    2023
  • 资助金额:
    $ 9.99万
  • 项目类别:
TIGIT in acute kidney injury and repair
TIGIT在急性肾损伤和修复中的作用
  • 批准号:
    10584173
  • 财政年份:
    2023
  • 资助金额:
    $ 9.99万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了